1. Home
  2. MERC vs KRRO Comparison

MERC vs KRRO Comparison

Compare MERC & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mercer International Inc.

MERC

Mercer International Inc.

HOLD

Current Price

$1.26

Market Cap

106.5M

ML Signal

HOLD

Logo Korro Bio Inc.

KRRO

Korro Bio Inc.

HOLD

Current Price

$10.77

Market Cap

109.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MERC
KRRO
Founded
1968
2014
Country
Canada
United States
Employees
N/A
87
Industry
Paper
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
106.5M
109.7M
IPO Year
2005
2019

Fundamental Metrics

Financial Performance
Metric
MERC
KRRO
Price
$1.26
$10.77
Analyst Decision
Hold
Buy
Analyst Count
3
12
Target Price
$2.50
$34.80
AVG Volume (30 Days)
374.2K
207.0K
Earning Date
04-30-2026
03-12-2026
Dividend Yield
11.54%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,169,145,000.00
$6,392,000.00
Revenue This Year
$13.75
N/A
Revenue Next Year
$10.12
N/A
P/E Ratio
N/A
N/A
Revenue Growth
25.50
181.46
52 Week Low
$1.27
$5.20
52 Week High
$6.78
$55.89

Technical Indicators

Market Signals
Indicator
MERC
KRRO
Relative Strength Index (RSI) 22.96 43.60
Support Level N/A $10.55
Resistance Level $2.30 $14.96
Average True Range (ATR) 0.10 0.89
MACD -0.04 -0.11
Stochastic Oscillator 4.31 6.50

Price Performance

Historical Comparison
MERC
KRRO

About MERC Mercer International Inc.

Mercer International Inc is a forest products company with two reportable operating segments in pulp and solid wood. The pulp segment consists of the manufacture, sale, and distribution of pulp, electricity, and chemicals. The company has a geographical presence in the USA, Germany, China, and Other countries, where the majority of revenue is generated from the USA. The majority of the revenue is generated from the Pulp segment.

About KRRO Korro Bio Inc.

Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.

Share on Social Networks: